Modifiedmedical mutual - ohioPolicy AHS - M2057

Diagnosis of Vaginitis

Customize your policy alerts

Sign up for medical mutual - ohio Policy AHS - M2057 alerts

Get alerted when Policy AHS - M2057 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policies governing laboratory and office diagnostic testing for vaginitis (including BV, vulvovaginal candidiasis, and trichomoniasis) for individuals presenting with signs or symptoms, specifying which tests meet coverage criteria and which do not.

Policy Summary

Payermedical mutual - ohio

PolicyDiagnosis of Vaginitis

Policy CodePolicy AHS - M2057

Change TypeMaterial revisions and coding updates

Effective DateFeb 1, 2026

Last ReviewSep 4, 2025

Next Review DateSep 4, 2025

Key ActionOnly perform NAAT panel testing for symptomatic individuals and limit repeat panel testing to no more than once every seven days; document symptoms and in-office findings.

SourceLink

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

Modifiedmedical mutual - ohioPolicy AHS - M2057

Diagnosis of Vaginitis

Customize your policy alerts

Sign up for medical mutual - ohio Policy AHS - M2057 alerts

Get alerted when Policy AHS - M2057 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

Payermedical mutual - ohio

PolicyDiagnosis of Vaginitis

Policy CodePolicy AHS - M2057

Change TypeMaterial revisions and coding updates

Effective DateFeb 1, 2026

Last ReviewSep 4, 2025

Next Review DateSep 4, 2025

Key ActionOnly perform NAAT panel testing for symptomatic individuals and limit repeat panel testing to no more than once every seven days; document symptoms and in-office findings.

SourceLink

POLICY UPDATE CHANGES

Individual organism testing for T. vaginalis moved to G2157 and several coverage criteria (CC4, CC5, CC10) were removed or renumbered; qualitative NAAT for Candida was specified for complicated VVC.

NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis) is covered no more than once every seven days (see Note 1).

New Note 1: do not repeat NAAT panel testing before a minimum treatment window has passed; individual organism testing may be performed within this window if symptoms persist.

Added CPT code 0068U and CPT code 0557U; removed CPT codes 87661 and 87808.

For complicated vulvovaginal candidiasis (VVC), qualitative PCR-based identification of Candida meets coverage criteria.

1 test/7 daysNAAT panel frequency limit

7numbered coverage statements

90-99%reported sensitivity range

1.18Mpatients in utilization study

72evidence references

2CPT codes added

2CPT codes removed

Coverage Criteria for Vaginitis Diagnostic Testing

inv-01: Covered diagnostic tests for symptomatic individuals

Covered when individuals present with signs and symptoms of vaginitis:

Office/Initial diagnostic tests: pH testing, amine (whiff) testing, measurement of sialidase activity, saline wet mount, potassium hydroxide (KOH) wet mount, and microscopic examination of vaginal fluids meet coverage criteria.

Molecular/Probe tests: Direct probe DNA-based identification of Gardnerella, Trichomonas, and Candida (e.g., BD Affirm VPIII) meets coverage criteria.

Culture for Candida: Vaginal cultures for Candida species meet coverage criteria when wet-mount preparations are negative and pH is normal.

PCR for complicated VVC: Qualitative PCR-based identification of Candida to confirm clinical diagnosis and identify non-albicans Candida meets coverage criteria for complicated vulvovaginal candidiasis.

NAAT for BV: NAAT specific to diagnosis of BV (e.g., Aptima BV; OneSwab BV Panel PCR with Lactobacillus profiling; SureSwab Advanced BV, TMA) and single/multitarget PCR testing meet coverage criteria for symptomatic individuals.

NAAT vaginitis panels: NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis) meets coverage criteria for symptomatic individuals; limited to no more than one test every seven days (see Note 1).<=1 per 7 days

See Note 1 regarding minimum treatment window.

inv-02: Not covered / Does not meet coverage criteria

The following testing is not covered:

Asymptomatic screening: Screening for trichomoniasis and bacterial vaginosis in asymptomatic individuals, including asymptomatic pregnant individuals at average or high risk for premature labor, does not meet coverage criteria.

NAAT for Candida in non-indicated situations: NAAT testing for Candida (e.g., quantitative NAAT testing) outside the symptomatic scenarios described does not meet coverage criteria.

Molecular panels for flora/infertility: Testing for microorganisms involved in vaginal flora imbalance and/or infertility using molecular-based panel testing does not meet coverage criteria due to insufficient published evidence.

Broad concurrent STI/vaginitis panels not addressed: Broad molecular panels designed to concurrently test for vaginitis and various other STIs not addressed above do not meet coverage criteria.

inv-03: Coverage criteria for diagnostic testing

Covered when ALL of the following are met

Symptomatic testing indication: Patient has symptoms consistent with vaginitis (vaginal discharge, odor, or itch) documented in the medical record

CDC states BV NAATs should be used among symptomatic women only (accuracy not well defined for asymptomatic women).

Appropriate diagnostic method: One of: in-office microscopy/pH/KOH/Amsel criteria or molecular NAAT/TMA panel or validated point-of-care test relevant to the suspected pathogen

Traditional methods remain useful for symptomatic BV due to lower cost and rapid diagnosis; molecular tests appropriate when microscopy unavailable or higher sensitivity needed.

inv-04: Covered when criteria met

Covered diagnostic testing for vaginitis in symptomatic patients when documentation supports clinical presentation consistent with vaginitis/vaginosis.

Symptomatic use requirement: Multiplex NAATs and other diagnostic tests are intended for women with symptoms consistent with vaginitis (e.g., discharge, odor, itch); accuracy for asymptomatic women is not well definedsymptomatic

CDC and IDSA state NAATs should be used among symptomatic women only

Acceptable diagnostic methods: Amsel clinical criteria OR Gram stain with Nugent scoring OR approved multiplex NAATs OR microscopy with KOH for VVC

ACOG recommends Amsel or Nugent for BV; CDC and IDSA discuss NAATs as accurate alternatives

LDT and FDA-cleared distinction: FDA-cleared multiplex assays (e.g., BD Max, Aptima) have published performance characteristics; laboratory-developed tests require internal validation and CLIA high-complexity oversight

Document LDT validation when used for patient care

inv-05: Not covered / limited indications

Not intended uses / limited coverage

Asymptomatic screening: Multiplex NAATs are not intended for screening asymptomatic patients and should not be used for screening in pregnancy except per specific high-risk guidanceasymptomatic

CDC/IDSA caution against use in asymptomatic patients; USPSTF recommends against BV screening in low-risk pregnant persons

Test of cure / prognostic use: Multiplex NAATs are not to be used as a test of cure or for prognostic purposespost-treatment

IDSA states multiplex tests are not intended as test of cure

inv-06: Covered testing scenarios

Covered when specific criteria are met and subject to frequency limits

Complicated VVC: For individuals with complicated vulvovaginal candidiasis (VVC), qualitative polymerase chain reaction (PCR) based identification of Candida to confirm clinical diagnosis and identify non-albicans Candida MEETS COVERAGE CRITERIA.

Qualitative NAAT specified.

NAAT panel for signs/symptoms: For individuals with signs and symptoms of vaginitis, NAAT panel testing (no more than one test every seven days) designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis) MEETS COVERAGE CRITERIA.<=1 per 7 days

See Note 1: do not repeat NAAT panel testing before the minimum treatment window has passed; individual organism testing may be performed within this window if symptoms persist.

inv-07: Not medically necessary / Excluded tests

Other Candida NAAT: For all other situations not described above, NAAT testing for Candida (e.g., quantitative NAAT testing) DOES NOT MEET COVERAGE CRITERIA.

Quantitative NAAT for Candida not covered outside specified scenarios.

Broad STI+Vaginitis panels: All other tests for vaginitis (e.g., broad molecular panels designed to concurrently test for vaginitis and various other STIs) not addressed above DO NOT MEET COVERAGE CRITERIA.

Broad panels excluded due to insufficient evidence.

Broad molecular panels that target vaginal flora imbalance, infertility-related organisms, or use a single swab to test for a wide range of pathogens (for example, multi‑organism tests like AMPLISwab™) are considered experimental or not supported by sufficient evidence and thus DO NOT MEET COVERAGE CRITERIA. The policy explicitly excludes molecular panel testing intended to assess microorganisms involved in vaginal flora imbalance and/or infertility, and excludes broad panels designed to concurrently test for vaginitis and various other STIs.

Note that the policy's revision history adds a clarifying frequency limit for allowed NAAT vaginitis panels: NAAT panel testing designed to detect more than one type of vaginitis is covered for symptomatic individuals but limited to no more than one test every seven days; see Note 1 for the minimum treatment/repeat testing window.

Routine screening of asymptomatic pregnant women for bacterial vaginosis is not supported for prevention of preterm birth and therefore such screening DOES NOT MEET COVERAGE CRITERIA in the absence of a specific clinical indication. The policy cites USPSTF guidance discouraging BV screening in pregnant persons not at increased risk for preterm delivery.

More broadly, screening for trichomoniasis and bacterial vaginosis in asymptomatic individuals (including pregnant individuals) is listed among services that do not meet coverage criteria and may be denied if submitted without appropriate symptomatic documentation.

The policy states that NAATs for bacterial vaginosis should be used among symptomatic women only because accuracy is not well defined for asymptomatic women; therefore screening asymptomatic women with BV NAATs is discouraged. Traditional diagnostic methods (Amsel criteria, Nugent score, microscopy) remain useful for symptomatic BV due to lower cost and rapid results.

Cervical Pap tests have no clinical utility for diagnosing BV because of low sensitivity and specificity and therefore are not appropriate to detect BV.

Procedure codes listed in Medical Policy documents are provided as a general reference and may not be all‑inclusive. Inclusion on the code list does not guarantee coverage in every circumstance; providers must ensure claims are supported by the policy criteria and clinical documentation.

Broad molecular panels that concurrently test for vaginitis and other sexually transmitted infections (for example, large multi‑organism panels that include STIs beyond the scope of vaginitis diagnostics) are explicitly excluded from coverage and DO NOT MEET COVERAGE CRITERIA unless an allowed, specific indication is documented.

The policy revision reiterates the exclusion of broad concurrent STI/vaginitis panels and clarifies that NAAT panels intended to detect multiple vaginitis pathogens are subject to frequency limits when covered for symptomatic patients.

Asymptomatic screening for bacterial vaginosis and trichomoniasis and NAAT testing for Candida in individuals without symptoms are considered NOT MEDICALLY NECESSARY and do not meet coverage criteria. The policy identifies these scenarios as potential denial triggers if submitted without documentation of signs or symptoms consistent with vaginitis.

BV NAAT testing in asymptomatic women is specifically discouraged due to unclear accuracy and lack of guideline support; similarly, quantitative NAATs for Candida outside of specified, covered situations are not supported.

BV NAAT testing is appropriate for diagnosis only in women who are symptomatic (e.g., vaginal discharge, odor, or itch); use of BV NAATs for asymptomatic screening is discouraged and may be outside recommended use. The policy notes CDC guidance that BV NAATs should be used among symptomatic women only because accuracy is not well defined for asymptomatic populations.

Testing asymptomatic women with BV NAATs or routine retesting (test‑of‑cure) in the absence of symptoms is not supported by guideline evidence and may not meet coverage criteria.

The policy does not support routine use of BV NAATs in asymptomatic women and specifically states that repeating NAAT panels before an adequate treatment window has passed is not supported. Note 1 clarifies that NAAT panel testing for multiple vaginitis targets should not be repeated before the minimum treatment window (up to a seven‑day course for trichomoniasis) has passed; individual organism testing may be considered sooner if symptoms persist.

Overall, use of BV NAATs and routine retesting in asymptomatic patients is not supported and may be denied when submitted without symptomatic indications.

Quantitative NAAT testing for Candida is specifically identified as not meeting coverage criteria in situations other than the covered scenarios (for example, complicated VVC where qualitative PCR is specified). For all other situations, quantitative Candida NAATs are considered NOT MEDICALLY NECESSARY and do not meet coverage criteria.

The policy revision clarifies that qualitative PCR‑based identification of Candida meets coverage criteria for complicated vulvovaginal candidiasis, while quantitative NAAT approaches for Candida outside that indication are excluded.

Applicable Procedure and Reference Codes

Applicable CPT/HCPCS procedure codes section referencedmixed

No codes listed

Applicable CPT/HCPCS Procedure CodesCPT/HCPCS

81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative result for bacterial vaginosis.
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, BVAB-2, and Lactobacillus species, utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis; includes separate detection of Trichomonas vaginalis and/or Candida species when reported.
81515	Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megasphaera type 1, and BVAB-2, utilizing vaginal-fluid specimens, algorithm reported as positive or negative for high likelihood of bacterial vaginosis; includes separate detection of Trichomonas vaginalis and Candida species when reported.
82120	Amines, vaginal fluid, qualitative.
83986	pH; body fluid, not otherwise specified.
87070	Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates.
87149	Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed.

Covered CPT/HCPCS Codes (laboratory and molecular diagnostics)CPTCovered

81513	Infectious disease, bacterial vaginosis, quantitative real-time amplification of RNA markers for Atopobium vaginae, Gardnerella vaginalis, and Lactobacillus species, vaginal-fluid specimens, algorithm reported positive/negative for bacterial vaginosis
81514	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, BVAB-2, Lactobacillus species; includes separate detection of Trichomonas vaginalis and/or Candida species
81515	Infectious disease, bacterial vaginosis and vaginitis, real-time PCR amplification of DNA markers for Atopobium vaginae, Atopobium species, Megasphaera type 1, and BVAB-2; includes separate detection of Trichomonas vaginalis and Candida species when reported
82120	Amines, vaginal fluid, qualitative
83986	pH; body fluid, not otherwise specified

Covered CPT/HCPCS Codes (culture, probe, multiplex, enzymatic tests)CPTCovered

87070	Culture, bacterial; any other source except urine, blood or stool, aerobic, with isolation and presumptive identification of isolates
87149	Culture, typing; identification by nucleic acid (DNA or RNA) probe, direct probe technique, per culture or isolate, each organism probed
87150	Culture, typing; identification by nucleic acid (DNA or RNA) probe, amplified probe technique, per culture or isolate, each organism probed
87210	Smear, primary source with interpretation; wet mount for infectious agents (e.g., saline, India ink, KOH preps)
87480	Infectious agent detection by nucleic acid; Candida species, direct probe technique
87481	Infectious agent detection by nucleic acid; Candida species, amplified probe technique
87482	Infectious agent detection by nucleic acid; Candida species, quantification
87510	Infectious agent detection by nucleic acid; Gardnerella vaginalis, direct probe technique
87511	Infectious agent detection by nucleic acid; Gardnerella vaginalis, amplified probe technique
87512	Infectious agent detection by nucleic acid; Gardnerella vaginalis, quantification

1–10 of 17

1/2

Proprietary / U-codes and other lab-specific codesHCPCS / CPT / ProprietaryCovered

0068U	Candida species panel (C. albicans, C. glabrata, C. parapsilosis, C. kruseii, C. tropicalis, and C. auris), amplified probe technique with qualitative report of the presence or absence of each species; Proprietary test: MYCODART-PCR™ Dual Amplification Real Time PCR Panel for 6 Candida species
0330U	Infectious agent detection by nucleic acid, vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab; Proprietary test: Bridge Women's Health Infectious Disease Detection Test
0505U	Swab, real-time PCR, reported as positive or negative for each organism; Proprietary test: Vaginal Infection Testing
0557U	Infectious disease (bacterial vaginosis and vaginitis), real-time amplification of DNA markers for multiple organisms including BV and STIs, vaginal fluid, reported as detected or not detected for each organism; Proprietary test: HealthTrackRx Vaginitis
Q0111	Wet mounts, including preparations of vaginal, cervical or skin specimens

Policy coding changesCPT

0068U	Added CPT code (policy notes addition)
0557U	Added CPT code (off-cycle coding modification)
87661	Removed CPT code
87808	Removed CPT code

inv-23: NAAT panel repeat interval (summary key/value)

Policy frequency limitNAAT panel testing designed to detect more than one type of vaginitis is allowed no more than one test every seven days.

Repeat testing exceptionNAAT panel testing should not be repeated before the minimum treatment window has passed; when symptoms persist, individual organism testing may be performed within the window.

Source guidanceNote 1 references CDC recommendations specifying a seven-day minimum treatment window (longest minimum treatment is seven days for trichomoniasis).

inv-24: Nugent or quantitative PCR thresholds (study citations; no numeric thresholds provided)

Document statement

Provider Actions, Documentation, and Billing Guidance

Prior Authorization

NAAT panel frequency limit — 1 test/7 days

NAAT panel testing designed to detect more than one type of vaginitis (VVC, BV, and/or trichomoniasis) is allowed no more than one test every seven days; repeat panel testing before the minimum treatment window has passed is not supported (see Note 1).

Limit: no more than one NAAT panel per 7 days
Do not repeat panel testing before minimum treatment window (Note 1)

Prior Authorization

Prior authorization guidance for syndromic PCR testing

Syndromic molecular PCR (multiplex NAAT) testing may be clinically useful and cost‑saving for symptomatic patients, but prior authorization may be required where molecular panel testing is higher cost — document symptoms and prior in‑office testing to justify use.

Document signs/symptoms and prior in‑office tests (pH, KOH, wet mount) when requesting syndromic PCR panels
Prior authorization may be required by payer policy for higher‑cost molecular panels

Background and Context

Vaginitis is inflammation of the vagina presenting with symptoms such as vaginal discharge, odor, itching, or discomfort. The most common infectious causes are bacterial vaginosis (BV), vulvovaginal candidiasis (VVC), and trichomoniasis.

Traditional bedside and laboratory diagnostics include measurement of vaginal pH, Amsel clinical criteria, and microscopic examination (wet mount/KOH) with Nugent scoring for Gram stain. These methods remain useful for symptomatic patients because they are rapid and lower cost; molecular NAAT/PCR assays offer higher sensitivity and can detect mixed infections but have limitations when used for asymptomatic screening.

Definitions and Test Types

inv-49: NAAT — nucleic acid amplification testing

DefinitionNAAT = Nucleic acid amplification testing (molecular methods such as PCR or TMA to detect pathogen nucleic acids).

Acronym listTerm and definition appear in the policy Table of Terminology under IV: NAAT defined as Nucleic acid amplification testing.

Use notePolicy distinguishes NAATs as molecular diagnostics used for symptomatic vaginitis evaluation and in some FDA-cleared multiplex assays.

inv-50: BV — bacterial vaginosis

DefinitionBV = Bacterial vaginosis.

Clinical relevanceBV is one of the most common causes of vaginitis symptoms (discharge, odor) referenced throughout the policy.

Policy Revision History

2026-02-01Policy effective date

Policy AHS - M2057 became effective with revised coverage language and updates to testing specifications.

2025-09-04Reviewed and updated

Reviewed and updated background, guidelines, and evidence references; clarified that individual organism testing for T. vaginalis moved to policy G2157 and specified qualitative NAAT for complicated VVC.

2025-06-04Revision (coding and frequency limits)Latest

Policy Summary

Payermedical mutual - ohio

PolicyDiagnosis of Vaginitis

Policy CodePolicy AHS - M2057

Change TypeMaterial revisions and coding updates

Effective DateFeb 1, 2026

Last ReviewSep 4, 2025

Next Review DateSep 4, 2025

Key ActionOnly perform NAAT panel testing for symptomatic individuals and limit repeat panel testing to no more than once every seven days; document symptoms and in-office findings.

SourceLink

On This Page

The document cites studies comparing quantitative real-time PCR assays with clinical/Gram stain (Nugent) for bacterial vaginosis but does not specify numeric diagnostic thresholds in the policy text.

Representative citationReference: Menard JP et al., Diagnostic accuracy of quantitative real-time PCR assay versus clinical and Gram stain identification of bacterial vaginosis (Eur J Clin Microbiol Infect Dis. 2010).

Context from CDC/analytical validityPCR-based assays to quantify BV-associated bacteria have good sensitivity and specificity compared with standard clinical tests, but are noted as expensive and of limited utility; numeric thresholds are not provided in policy text.

inv-25: Repeat NAAT panel interval (duplicate reference)

Repeat interval reiteratedPolicy restates NAAT panel testing limit: no more than one test every seven days for multiplex vaginitis panels.

Note on treatment windowDo not repeat NAAT panel testing before the minimum treatment window has passed; individual organism testing may be done sooner if symptoms persist.

Examples referencedExamples of multiplex panels referenced with this interval include BD MAX Vaginal Panel, NuSwab VG, and Xpert Xpress MVP in the revision notes.

Documentation Required

LDT validation and CLIA oversight requirements

Laboratory‑developed tests (LDTs) must be internally validated and are performed under CLIA high‑complexity oversight; documentation of test validation may be required for non–FDA‑cleared assays used for patient care.

LDTs are regulated under CLIA and require internal validation
Provide validation/CLIA oversight documentation for LDTs when requested

Billing Rule

Applicable procedure codes — provider billing reminder

Use the policy’s listed CPT/HCPCS and proprietary procedure codes as the reference for vaginitis diagnostics and ensure correct code use when billing (examples include 81513–81515, 87210, 87480–87482, 87660, 0068U, 0557U, Q0111).

Codes listed in the policy are for reference; verify appropriate code(s) prior to billing
Examples: 81513, 81514, 81515, 87210, 87480–87482, 87660, 0068U, 0557U, Q0111

Billing Rule

Coding changes and frequency constraint

Policy was updated with off‑cycle coding modifications: CPT codes 0068U and 0557U were added and CPT codes 87661 and 87808 were removed; coverage remains tied to policy clinical criteria and frequency limits (e.g., NAAT panels ≤1 per 7 days).

Added codes: 0068U, 0557U
Removed codes: 87661, 87808
Coverage determined by meeting clinical criteria and frequency constraints

Step Therapy

Minimum seven‑day treatment window before repeat panel testing

Per Note 1 (CDC‑based), the longest minimum treatment course among organisms on allowed vaginitis panels is seven days for trichomoniasis; NAAT panel testing should not be repeated before this minimum seven‑day treatment window has passed.

Minimum treatment window before repeat panel testing: 7 days
If symptoms persist despite treatment, individual organism testing may be performed within the window

Step Therapy

Testing sequence preference — microscopy/POC first

When available and adequate, begin with point‑of‑care and microscopy (pH, KOH, wet mount, Amsel criteria) before ordering molecular NAAT panels; molecular testing is appropriate when microscopy is unavailable or higher sensitivity is needed.

Use microscopy/pH/KOH/Amsel as initial evaluation when available
Order molecular NAATs if traditional methods are unavailable or higher diagnostic accuracy is required

Step Therapy

Preference for traditional diagnostics as lower‑cost initial evaluation

Traditional diagnostic methods (Amsel criteria, Nugent score, microscopy/KOH) remain useful and lower‑cost initial evaluations for symptomatic BV and VVC and should be used when feasible before molecular testing.

Amsel and Nugent remain recommended for BV diagnosis in symptomatic women
Microscopy/KOH and wet mount are appropriate first‑line, lower‑cost options

Documentation Required

Testing covered when signs/symptoms present — documentation required

Testing is covered when individuals present with signs and symptoms of vaginitis; include documentation of signs and symptoms and relevant test findings (e.g., pH, wet mount results) with the request.

Document presenting signs/symptoms (discharge, odor, itch) in the medical record
Include in‑office test results (pH, wet mount, KOH) when available

Documentation Required

Clinical documentation for vaginitis testing — required elements

Clinical documentation should include history, symptoms (discharge, odor, itch), exam findings, and results of available in‑office tests (pH, KOH, wet mount); note that NAATs are recommended for symptomatic women when traditional methods are unavailable or higher sensitivity is desired.

Record relevant history including sexual practices, menses, hygiene, and prior treatments
Record in‑office test findings and source of specimen (clinician‑ or patient‑collected swab)

Documentation Required

Clinical presentation and specimen source — document symptomatic female and swab source

Tests and NAAT panels are intended for females with a clinical presentation consistent with vaginitis/vaginosis; documentation should support symptomatology and indicate clinician‑ or patient‑collected vaginal swab as specimen source.

Confirm clinical presentation consistent with vaginitis (discharge, odor, itch) in documentation
State specimen source: clinician‑collected or patient‑collected vaginal swab

Note

Policy currency and verification — check payer site

Verify the most current version of this policy at https://www.medmutual.com/LabPolicies before relying on printed copies, as the online document is the authoritative source.

Official policy updates and coding changes are posted at the payer site
Printed copies may be out of date

Documentation Required

Documentation expectations — note qualitative vs quantitative NAAT; respect minimum window

Document the NAAT test type (qualitative vs quantitative) in the record and note that NAAT panel testing should not be repeated before the minimum treatment window (Note 1) has passed.

For complicated VVC, qualitative PCR‑based NAAT for Candida is the specified type
Do not repeat NAAT panel testing before the minimum treatment window

Denial Risk

Asymptomatic screening for trichomoniasis and BV not covered

Do not submit NAATs for trichomoniasis or BV for asymptomatic individuals—screening for these conditions in asymptomatic persons does not meet coverage criteria and may be denied.

Asymptomatic screening for trichomoniasis and BV is not covered
Include symptomatic indication to avoid denial

Denial Risk

NAAT for Candida in non‑symptomatic situations does not meet coverage

NAAT testing for Candida (including quantitative NAAT) performed outside the symptomatic scenarios described in the policy does not meet coverage criteria and may be denied.

Quantitative Candida NAAT in non‑covered situations is not medically necessary
For complicated VVC, qualitative PCR is the covered NAAT type

Denial Risk

Broad molecular panels for flora/infertility or concurrent STI panels not allowed

Broad molecular panels aimed at vaginal flora imbalance/infertility or broad panels concurrently testing for vaginitis and other STIs are excluded from coverage and do not meet coverage criteria.

Panels testing for organisms related to infertility or broad concurrent STI/vaginitis panels are not covered
These panels lack sufficient published evidence per the policy

Denial Risk

BV NAATs appropriate only for symptomatic women

BV NAATs are appropriate only for symptomatic women; performing BV NAAT testing for asymptomatic women may be outside recommended use and could result in denial if submitted without symptomatic indication.

Use BV NAATs only when symptoms (discharge, odor, itch) are present
Do not use BV NAATs for routine asymptomatic screening

Denial Risk

NAAT use limited to symptomatic patients — do not screen asymptomatic individuals

Multiplex NAATs and other molecular panels are intended for symptomatic patients and are not intended for asymptomatic screening; using these tests for screening asymptomatic patients may risk noncoverage.

Multiplex tests are not intended as screening tools for asymptomatic patients
Avoid using multiplex NAATs for asymptomatic screening to prevent claim denials

Billing Rule

Coding reference caution — codes listed for reference only

Procedure codes in this policy are provided as a general reference and may not be exhaustive; claims using codes not listed may be at risk if not otherwise supported by policy or documentation—verify codes prior to submission.

Codes listed are not all‑inclusive; verify applicability to the service rendered
Unsupported or unlisted codes may trigger claim review or denial

Denial Risk

Denial triggers for out‑of‑criteria testing — expect denials for non‑covered NAATs and broad panels

NAAT testing for Candida (e.g., quantitative NAAT testing) for situations not described in the coverage criteria does not meet coverage and is a common denial trigger; broad molecular panels designed to concurrently test for vaginitis and other STIs are also excluded.

Quantitative Candida NAAT outside covered scenarios = not covered
Broad concurrent STI/vaginitis panels = not covered

Diagnostic noteCDC and ACOG guidance on BV testing (Amsel, Nugent, and NAATs) are discussed in the policy.

inv-51: VVC — vulvovaginal candidiasis

DefinitionVVC = Vulvovaginal candidiasis.

Diagnostic criteriaACOG recommends visualization of spores/pseudohyphae on wet-mount microscopy or positive vaginal fungal culture/commercial test for diagnosis of VVC.

Policy roleQualitative PCR-based identification of Candida is specified for complicated VVC per the policy revision notes.

inv-52: Amsel criteria definition

Amsel definitionAmsel criteria require at least three of: homogeneous thin vaginal discharge, vaginal pH > 4.5, positive KOH 'whiff' test (amine odor), and presence of clue cells on wet mount.

Diagnostic performanceWhen clinical criteria are used, reported sensitivity ranges from 62–100%; sensitivity >90% and specificity 77% when compared with Gram stain in some analyses.

Clinical recommendationAmsel remains a standard clinical diagnostic approach for symptomatic BV and is recommended by ACOG per the policy.

inv-53: Nugent score definition

Nugent definitionNugent score = Gram stain scoring system used to diagnose bacterial vaginosis based on morphologic evaluation of bacteria on a vaginal swab.

RoleNugent scoring is an accepted laboratory method for BV diagnosis and is recommended by ACOG alongside Amsel criteria.

Relation to PCRPolicy notes studies comparing quantitative PCR assays to Nugent scoring but does not provide numeric PCR thresholds in the policy text.

inv-54: NAAT (multiplex vaginal panel) definition

DefinitionNAAT (multiplex vaginal panel) = Molecular tests that detect nucleic acids from specific vaginal microbiota (e.g., G. vaginalis, A. vaginae, BVAB2, Megasphaera type 1, and certain Lactobacillus species); may include Candida spp. and Trichomonas detection.

VariantsAvailable as FDA-cleared assays (e.g., BD Max Vaginal Panel, Aptima BV) or as laboratory-developed tests (NuSwab VG, OneSwab BV Panel, SureSwab BV).

TurnaroundThese tests can be performed on clinician- or self-collected vaginal specimens with results available in <24 hours depending on platform.

inv-55: Amsel criteria / Nugent score — traditional diagnostic methods recommended by ACOG

RecommendationACOG recommends use of Amsel clinical criteria or Gram stain with Nugent scoring for diagnosis of BV (Level A evidence).

Guidance detailsACOG also states wet-mount microscopy, pH testing, and KOH whiff test are recommended for initial evaluation of vaginitis symptoms.

Panel commentACOG notes advanced single-swab multiplex PCR/DNA probe panels may be a promising alternative to microscopy for BV, trichomoniasis, and candidiasis.

inv-56: Wet mount (Q0111 / 87210) — microscopy-based diagnosis reference

Procedure codesQ0111 / 87210 refer to wet mount: smear, primary source with interpretation (e.g., saline, KOH preps) used in microscopy-based diagnosis of vaginitis.

Clinical useWet mount microscopy is used to visualize candidal elements, motile trichomonads, clue cells, and other findings during in-office evaluation.

Coverage noteMicroscopy and wet-mount preparations meet coverage criteria as initial diagnostic tests for symptomatic individuals per policy criteria.

inv-57: Molecular panels / proprietary tests — examples of codes like 81513-81515 and U-codes

Examples of molecular/proprietary codesPolicy lists CPT codes 81513–81515 and HCPCS/U-codes such as 0068U, 0330U, 0505U, 0557U as examples of nucleic acid amplification or proprietary multi-organism vaginal pathogen panels.

Code descriptionsThese codes represent quantitative or qualitative real-time PCR/amplified probe tests for BV, Candida, and multi-organism vaginal pathogen panels described in the applicable procedure codes section.

Billing cautionPolicy notes that procedure codes are provided as a reference and may not be all-inclusive; verify appropriate code use before billing.

inv-58: Note 1 — minimum treatment/repeat testing window (per CDC) for organisms on allowed panels

Minimum treatment/repeat testing window (Note 1)Per CDC recommendations, the longest minimum treatment for an organism on allowed vaginitis panels is a seven-day course (for trichomoniasis); NAAT panel testing should not be repeated before this minimum treatment window has passed.

Implication for practiceProviders should wait for the minimum treatment window before repeating multiplex NAAT panels; if symptoms persist, individual organism testing may be considered within the window.

Source referenceNote 1 in the policy explicitly references CDC guidance on treatment duration and repeat testing constraints.

inv-59: Qualitative NAAT for complicated VVC — qualitative PCR specified as appropriate NAAT type

Qualitative NAAT specifiedFor complicated vulvovaginal candidiasis (VVC), the policy specifies qualitative PCR-based identification of Candida as the appropriate NAAT type that meets coverage criteria.

Revision historyPolicy revision notes (09/04/2025 and 06/04/2025) indicate addition of 'qualitative' to define the correct NAAT type for complicated VVC and list this in coverage criteria.

Coverage implicationQuantitative NAAT testing for Candida is not covered outside the specified scenarios; qualitative PCR is the covered NAAT approach for complicated VVC.

Added explicit NAAT panel frequency limit (no more than one test every seven days) with new Note 1 describing the minimum treatment/repeat testing window; added CPT code 0068U and 0557U and removed CPT codes 87661 and 87808.